BioNTech SE is transitioning from a COVID-19 vaccine story to a late-stage oncology platform with a robust $17B cash position. Click to read why BNTX is a Buy.
Q4 2025 Earnings Call February 24, 2026 8:00 AM ESTCompany ParticipantsGraham Stanley - VP of Investor Relations & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results